Status:
COMPLETED
Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Symmetric Limited Morphea
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.
Eligibility Criteria
Inclusion
- Male and female subjects 18 years of age or older.
- Symmetric limited morphea.
Exclusion
- Known sensitivity to fluocinonide 0.05% cream.
- Clinical evidence of superinfected skin.
- Immunocompromised state (including previously documented HIV).
- Generalized Scleroderma.
- Previous history of skin cancer.
- Non-English speaking subjects.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00812188
Start Date
November 1 2004
End Date
November 1 2009
Last Update
February 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center at Dallas - Department of Dermatology Clinical Trials
Dallas, Texas, United States, 75390